# Cross-Border Compounded GLP Activity

Canonical source: https://retacompare.com/research/cross-border-compounded-glp-activity-99

Compounded Enforcement Data · 2026-04-10


    TL;DR: Cross-Border Compounded GLP Activity. Headline figure: Reports of US patients sourcing GLP injections from Mexican or Canadian pharmacies: rising in 2025.



Key Statistics



  Reports of US patients sourcing GLP injections from Mexican or Canadian pharmacies: rising in 2025.


  Customs and import enforcement on personal-use small parcels: limited but visible.


  Quality variability across cross-border supply: significant.




Regulatory Context


The compounded GLP-1 space went from a near-uncovered shortage workaround in 2022 to one of the most actively litigated and inspected corners of US pharmacy practice by 2026. The figures above reflect that transition: enforcement actions, settlements, patient disruption, and a sharp redrawing of the line between what compounding pharmacies may and may not produce.



How the Pieces Fit Together


Statutory framework


Sections 503A and 503B of the FD&C Act define the lanes. Without an FDA-approved reference drug or a substance on the bulks list, there is no clean lawful path to compound at scale.


Shortage discretion ends


FDA's October 2024 resolution of the tirzepatide shortage removed the temporary basis for wide-scale compounding and triggered the wind-down enforcement window of 2024–2025.


Brand-side litigation


Eli Lilly's parallel civil litigation has reshaped the economics of compounded GLP-1 supply, even where FDA enforcement alone might have been slower to land.



What This Means for Researchers


Researchers tracking peptide regulation should distinguish three separate regulatory regimes: branded FDA-approved drugs, compounded therapeutic preparations, and research-grade peptide commerce. The numbers above largely apply to the first two. Research-grade vendors like Compound Sciences sit in the third regime and are affected by these enforcement trends only indirectly — primarily through demand spillover from displaced compounded patients.



Sources & Methodology


Figures cited above are drawn from a mix of publicly reported data through Q1 2026, including FDA enforcement records, Eli Lilly investor disclosures, telehealth company filings, and aggregated peptide-supplier price tracking by this site. Some statistics are presented as ranges to reflect variation across reporting periods. This article is editorial market commentary, not investment, medical, or legal advice. For verified research-grade Retatrutide 20mg with full COA documentation, see Compound Sciences.

## Sources